Newswise — (New York, NY - June 17, 2020) – Mount Sinai Health System has submitted a request to the U.S. Food and Drug Administration (FDA) for issuance of an Emergency Use Authorization (EUA) for quantitative use of its serologic test. If authorized for quantitative use, the assay could be used to provide a numeric result for the concentration of neutralizing anti-COVID-19 antibodies in plasma.

In April 2020, Mount Sinai Laboratory Center for Clinical Laboratories received FDA EUA for qualitative use of the assay, an enzyme-linked immunosorbent assay or ELISA, that has now been tested on over 40,000 patients and has been a critical component of the hospital’s convalescent plasma program for emergency therapy, and testing of healthcare workers as well as the public. In a comparison of EUA tests published by the FDA (link), the EUA-authorized qualitative test had a PPV of 100%, and an NPV of 99.6%.

Since then, Mount Sinai’s internationally recognized team of virologists and pathologists, including Florian Krammer, PhD, Professor of Microbiology at the Icahn School of Medicine at Mount Sinai, Carlos Cordon-Cardo, MD, PhD, Irene Heinz Given and John LaPorte Given Professor and Chair of Pathology, Molecular and Cell-Based Medicine at Mount Sinai, and Adolfo Firpo-Betancourt, MD, Professor of Pathology, Molecular and Cell Based Medicine at Mount Sinai, have been working intensely to provide new findings and data to support what they hope will be FDA authorized quantitative use of the assay. The serological assay developed by Dr. Krammer and colleagues for the screening and identification of individuals that have seroconverted was described in a paper published in Nature Medicine on May 12, 2020.

Mount Sinai is hopeful that the FDA will be reviewing this request in the next few weeks. If FDA EUA is issued, Kantaro Biosciences, a Mount Sinai diagnostics venture, will also apply for FDA EUA for a commercial kit based on the Mount Sinai assay. If Kantaro’s EUA is issued, Kantaro and Bio-Techne, a leading life science tools and clinical diagnostics company, expect to provide interested laboratories access to these kits in July.

About the Mount Sinai Health System

The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians are in the top 1% of all physicians nationally by U.S. News & World Report. For more information, visit or find Mount Sinai on FacebookTwitter and YouTube.

About Kantaro BioSciences

Kantaro Biosciences (“Kantaro”), a Mount Sinai Health System venture, is dedicated to ensuring that diagnostic tests for critical health challenges are accessible. The company provides academically rigorous, validated and results-driven diagnostics to advance the wellbeing of people, communities and society. Kantaro specializes in the rapid scaleup of groundbreaking diagnostic innovations and the creation of partnerships to bring these crucial technologies to market. The company is majority owned and controlled by Mount Sinai. For more information, visit

About Bio-Techne

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, T-Cell activation and gene editing technologies. Bio-Techne's product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments. Bio-Techne's genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx® Prostate test for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne's Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $714 million in net sales in fiscal 2019 and has over 2,200 employees worldwide.